SJS Investment Consulting’s Aclaris Therapeutics ACRS Stock Holding History

SJS Investment Consulting’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$540	Buy	+102	New	+$455	﹤0.01%	2251

Other funds holding ACRS

TBWA

Three Bridge Wealth Advisors Los Altos, California $399M AUM 18.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

CFS

CRA Financial Services Northfield, New Jersey $868M AUM 25.66% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

SJS Investment Consulting's ACRS Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 102 shares worth $540. The stake represents ﹤0.01% of the portfolio and ranks #2251 among its holdings.

20 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

SJS Investment Consulting held 102 shares of Aclaris Therapeutics worth $540 as of Q2 2026.
Aclaris Therapeutics was a new SJS Investment Consulting position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2251 holding.
20 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.